Abstract
Cannabis derivatives produce their CNS effect through activation of the endocannabinoid system, a recently discovered signalling system comprising specific receptors, their intrinsic lipid ligands and the associated enzymatic machinery (transporters, biosynthetic and degradative enzymes). This review provides the latest preclinical and clinical breakthroughs on the endocannabinoid system's role in psychotic disorders such as schizophrenia. Data reported so far clearly indicate the presence of a dysregulation in the endocannabinoid system (both in term of cannabinoid receptors and endocannabinoid ligands) in animal models of psychosis as well as in schizophrenic patients. Based on these observations, the pharmacological modulation of the endocannabinoid system has been taken into account as a new therapeutic possibility for psychotic disorders. However, preclinical studies have not provided straightforward results, with both agonists and antagonists exhibiting positive, negative or even no effect. At human level, only cannabidiol, a non psychotropic phytocannabinoid, and the antagonist/inverse agonist rimonabant were tested, however additional controlled trials are required to confirm the therapeutic exploitation of these compounds. Another important aspect in studying the relationship between the endocannabinoid system and schizophrenia is the impact of Cannabis consumption on psychotic disorders, especially when this occurs at vulnerable ages such as adolescence. In fact literature from animal models support adolescence as a highly vulnerable age for the consequences of cannabis exposure on different domains (such as cognition and social behaviour) that are altered in psychotic disorders.
Keywords: Cannabinoid, cannabis, endocannabinoid system, psychosis, schizophrenia, animal models, human studies, CNS, dysregulation, controlled trials.
Current Pharmaceutical Design
Title:The Endocannabinoid System and Schizophrenia: Integration of Evidence
Volume: 18 Issue: 32
Author(s): Erica Zamberletti, Tiziana Rubino and Daniela Parolaro
Affiliation:
Keywords: Cannabinoid, cannabis, endocannabinoid system, psychosis, schizophrenia, animal models, human studies, CNS, dysregulation, controlled trials.
Abstract: Cannabis derivatives produce their CNS effect through activation of the endocannabinoid system, a recently discovered signalling system comprising specific receptors, their intrinsic lipid ligands and the associated enzymatic machinery (transporters, biosynthetic and degradative enzymes). This review provides the latest preclinical and clinical breakthroughs on the endocannabinoid system's role in psychotic disorders such as schizophrenia. Data reported so far clearly indicate the presence of a dysregulation in the endocannabinoid system (both in term of cannabinoid receptors and endocannabinoid ligands) in animal models of psychosis as well as in schizophrenic patients. Based on these observations, the pharmacological modulation of the endocannabinoid system has been taken into account as a new therapeutic possibility for psychotic disorders. However, preclinical studies have not provided straightforward results, with both agonists and antagonists exhibiting positive, negative or even no effect. At human level, only cannabidiol, a non psychotropic phytocannabinoid, and the antagonist/inverse agonist rimonabant were tested, however additional controlled trials are required to confirm the therapeutic exploitation of these compounds. Another important aspect in studying the relationship between the endocannabinoid system and schizophrenia is the impact of Cannabis consumption on psychotic disorders, especially when this occurs at vulnerable ages such as adolescence. In fact literature from animal models support adolescence as a highly vulnerable age for the consequences of cannabis exposure on different domains (such as cognition and social behaviour) that are altered in psychotic disorders.
Export Options
About this article
Cite this article as:
Zamberletti Erica, Rubino Tiziana and Parolaro Daniela, The Endocannabinoid System and Schizophrenia: Integration of Evidence, Current Pharmaceutical Design 2012; 18 (32) . https://dx.doi.org/10.2174/138161212802884744
DOI https://dx.doi.org/10.2174/138161212802884744 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Statins and Carotid Intima-Media Thickness Reduction: An Up-to-Date Review
Current Medicinal Chemistry New therapeutic effects of cilostazol in patients with ischemic disorders
Current Vascular Pharmacology Cognitive Functions under Anti-HER2 Targeted Therapy in Cancer Patients: A Scoping Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Berberine Nanoencapsulation Attenuates Hallmarks of Scoplomine Induced Alzheimer's-Like Disease in Rats
Current Reviews in Clinical and Experimental Pharmacology From Brain Ischemia-Reperfusion Injury to Possible Sporadic Alzheimers Disease
Current Neurovascular Research APP Transgenic Mouse Models and their Use in Drug Discovery to Evaluate Amyloid-β Lowering Therapeutics
CNS & Neurological Disorders - Drug Targets Role of Ischemic Blood-Brain Barrier on Amyloid Plaques Development in Alzheimers Disease Brain
Current Neurovascular Research Childhood and Adulthood Rural Residence Increases the Risk of Dementia: NEDICES Study
Current Alzheimer Research Psychological Interventions for Neuropsychiatric Disturbances in Mild and Moderate Alzheimer’s Disease: Current Evidences and Future Directions
Current Alzheimer Research Quantitative Electroencephalogram Analysis in Parkinson’s Disease
Neuroscience and Biomedical Engineering (Discontinued) Interindividual Variability in the Efficacy of Oral Antiplatelet Drugs: Definitions, Mechanisms and Clinical Importance
Current Pharmaceutical Design Use of Angiotensin Receptor Blockers and Risk of Alzheimer’s Disease: A Class Effect?
Current Reviews in Clinical and Experimental Pharmacology Cerebrovascular Amyloidosis and Dementia
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Pharmacotherapy and Prevention of Vascular Dementia
CNS & Neurological Disorders - Drug Targets Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Genetic Insights into Sporadic Parkinson's Disease Pathogenesis
Current Genomics Therapy of XDR TB with Thioridazine a Drug Beyond Patent Protection but Eligible for Patent “As New Use”
Recent Patents on Anti-Infective Drug Discovery Characterization of the Early CNS Stress Biomarkers and Profiles Associated with Neuropsychiatric Diseases
Current Genomics Antioxidants in Health, Disease and Aging
CNS & Neurological Disorders - Drug Targets Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design